Impact of Genetic Variants of Apolipoprotein E on Lipid Profile in Patients with Parkinson's Disease

Gregório, Michele Lima; Pinhel, Marcela Augusta Souza; Sado, Caroline L.; Longo, G.; Oliveira, F M O Fernanda Matos E; Amorim, Gisele S.; Nakazone, Marcelo Arruda; Florim, Greiciane Maria da Silva; Mazeti, Camila Montoro; Martins, Denise Poltronieri; Tognola, Waldir Antônio; Brandão, Antônio Carlos; Júnior, Sidney Pinheiro; Godoy, Moacir Fernandes de; Souza, Dorotéia Rossi Silva

doi:10.1155/2013/641515

Cited by 22 publications

(29 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study showed that among PD patients, homozygous apoE‐ε3/3 carriers had higher levels of HDL‐C . Interestingly, results of one preliminary study revealed that tetranectin and apoA‐I were differentially expressed in the CSF of PD patients compared to normal controls .…”

Section: Role Of Hdls In Neurological Diseasesmentioning

confidence: 96%

Emerging roles for high‐density lipoproteins in neurodegenerative disorders

et al. 2019

View full text Add to dashboard Cite

Lipoproteins are the complexes of different lipids and proteins, which are devoted to the transport and clearance of lipids or lipid‐related molecules in the circulation. Lipoproteins have been found to play a crucial role in brain function and may influence myelination process. Among lipoproteins, high‐density lipoproteins (HDLs) and their major protein component, apoA‐I, are directly involved in cholesterol efflux in the brain. It has been suggested that inadequate or dysfunctional brain HDLs may contribute to cerebrovascular dysfunctions, neurodegeneration, or neurovascular instability. HDL deficiency could also promote cognitive decline through impacting on atherosclerotic risk. The focus of this review is to discuss knowledge on HDL dysregulation in neurological disorders. A better understanding on how changes in cellular HDL and apolipoprotein homeostasis affect central nervous system function may provide promising novel avenues for the treatment of specific HDL‐related neurological disorders.

show abstract

Section: Role Of Hdls In Neurological Diseasesmentioning

confidence: 96%

Emerging roles for high‐density lipoproteins in neurodegenerative disorders

et al. 2019

View full text Add to dashboard Cite

show abstract

“…One study showed that PD patients had increased levels of HDL cholesterol but did not include age- and sex-matched normal controls (Cassani et al, 2013). Another study found that only APOE -ε3/3 homozygous PD patients have increased levels of HDL cholesterol (Gregorio et al, 2013). Intriguingly, robust association between apoA-I levels and PD has been reported.…”

Section: Genetic Clinical and Experimental Evidence For Protective Ementioning

confidence: 99%

HDL and cognition in neurodegenerative disorders

Hottman

Chernick

Cheng

et al. 2014

Neurobiology of Disease

131

119

View full text Add to dashboard Cite

High-density lipoproteins (HDL) are a heterogeneous group of lipoproteins composed of various lipids and proteins. HDL is formed both in the systemic circulation and in the brain. In addition to being a crucial player in the reverse cholesterol transport pathway, HDL possesses a wide range of other functions including anti-oxidation, anti-inflammation, pro-endothelial function, anti-thrombosis, and modulation of immune function. It has been firmly established that high plasma levels of HDL protect against cardiovascular disease. Accumulating evidence indicates that the beneficial role of HDL extends to many other systems including the central nervous system. Cognition is a complex brain function that includes all aspects of perception, thought, and memory. Cognitive function often declines during aging and this decline manifests as cognitive impairment/dementia in age-related and progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A growing concern is that no effective therapy is currently available to prevent or treat these devastating diseases. Emerging evidence suggests that HDL may play a pivotal role in preserving cognitive function under normal and pathological conditions. This review attempts to summarize recent genetic, clinical and experimental evidence for the impact of HDL on cognition in aging and in neurodegenerative disorders as well as the potential of HDL-enhancing approaches to improve cognitive function.

show abstract

“…Furthermore, other genes re1ated to PD, such as APOE, GSTs and LRRK2 (PARK8), also showed no difference between patients and controls in this population 20,21,22,23 . On the other hand, mutations in the genes GIGYF (PARK11), ATP13A2 (PARK9) and GBA were associated with PD 6 .…”

Section: Discussionmentioning

confidence: 71%

Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson’s disease patients

Longo

Pinhel

Gregório

et al. 2015

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

Parkinson's disease (PD) is one of the major degenerative disorders, affecting 2% of the population over 65 years and up to 4% in people over 85 years 1 . In Brazil, statistics show that the incidence of PD amounts to 150/200 cases per 100,000 inhabitants 2 . Most cases of PD are idiopathic 3 . However, in approximately 5%-10% of the cases, there is a genetic component with both dominant and recessive inheritance patterns 3 . The chromosomal loci linked to the familial forms of PD are termed PARK1-13. These loci include six autosomal dominant genes [PARK 1or PARK 4 (alpha synuclein -SNCA), PARK 3 (Lewy bodies), PARK 5 (ubiquitin carboxyl-terminal esterase L1 -UCHL1), PARK 8 (leucine-rich repeat kinase 2 -LRRK2) and PARK13 (HTRA serine peptidase 2 -HTRA2)], 4 recessives genes [PARK 2 ABSTRACT Introduction:The pathogenesis of Parkinson's disease (PD) involves both genetic susceptibility and environmental factors, with focus on the mutation in the alpha-synuclein gene (SNCA). Objective: To analyse the polymorphism SNCA-A53T in patients with familial PD (FPD) and sporadic PD (SPD). Method: A total of 294 individuals were studied, regardless of sex and with mixed ethnicity. The study group with 154 patients with PD, and the control group included 140 individuals without PD. The genotyping of SNCA-A53T was performed by PCR/RFLP. Significance level was p < 0.05. Results: Among all patients, 37 (24%) had FPD and 117 (75.9%) had SPD. The absence of SNCA-A53T mutation was observed in all individuals. Conclusion: SPD is notably observed in patients. However, the SNCA-A53T mutation was absent in all individuals, which does not differ controls from patients. This fact should be confirmed in a Brazilian study case with a more numerous and older population. Keywords:Parkinson's disease, alpha-synuclein, mutation. RESUMO Introdução:A patogênese da doença de Parkinson (DP) envolve fatores ambientais e suscetibilidade genética, destacando-se a mutação de alfa-sinucleína (SNCA.) Objetivos: Analisar a variante genética SNCA-A53T em pacientes com DP familiar (DPF) e DP esporádica (DPE). Método: Foram estudados 294 indivíduos, independente de sexo, com etnia miscigenada, sendo 154 com DP e 140 sem a doença (grupo controle). A genotipagem de SNCA-A53T foi realizada por PCR/RFLP. Nível de significância para p < 0,05. Resultados: Entre os pacientes, 37(24%) tinham DPF e 117 (75,9%) DPE. A ausência da mutação SNCA-A53T em todos os indivíduos. Conclusão: DPE é destacada entre os pacientes, no entanto a mutação SNCA-A53T ausente em todos os indivíduos, não diferenciando os grupo controle e pacientes, o que deve ser confirmado em população brasileira, considerando uma ampla casuística, além da ancestralidade.Palavras-chave: doença de Parkinson, alfa sinucleína, mutação.

show abstract

Impact of Genetic Variants of Apolipoprotein E on Lipid Profile in Patients with Parkinson's Disease

Cited by 22 publications

References 59 publications

Emerging roles for high‐density lipoproteins in neurodegenerative disorders

Emerging roles for high‐density lipoproteins in neurodegenerative disorders

HDL and cognition in neurodegenerative disorders

Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson’s disease patients

Contact Info

Product

Resources

About